Silo Pharma (Nasdaq: SILO) has introduced a strategic enlargement into cryptocurrency treasury administration, specializing in Bitcoin, Ethereum, and Solana. The corporate has appointed crypto infrastructure skilled Corwin Yu as the primary member of its new Crypto Advisory Board to spearhead this initiative.
The technique consists of opportunistic digital forex purchases and yield era by staking, supported by newly acquired AI-powered market intelligence know-how. Concurrently, Silo Pharma continues its biopharmaceutical focus, with its PTSD drug SPC-15 approaching FDA IND utility submission.
Silo Pharma (Nasdaq: SILO) ha annunciato un’espansione strategica nella gestione del tesoro in criptovalute, concentrandosi su Bitcoin, Ethereum e Solana. L’azienda ha nominato l’esperto di infrastrutture crypto Corwin Yu come primo membro del nuovo Crypto Advisory Board per guidare questa iniziativa.
La strategia prevede acquisti opportunistici di valute digitali e generazione di rendimenti tramite staking, supportati da una nuova tecnologia di intelligenza artificiale per l’analisi del mercato. Contemporaneamente, Silo Pharma mantiene il suo focus biofarmaceutico, con il farmaco per il PTSD SPC-15 che si avvicina alla presentazione della domanda IND alla FDA.
Silo Pharma (Nasdaq: SILO) ha anunciado una expansión estratégica en la gestión de tesorería en criptomonedas, enfocándose en Bitcoin, Ethereum y Solana. La compañía ha designado al experto en infraestructura cripto Corwin Yu como el primer miembro de su nuevo Crypto Advisory Board para liderar esta iniciativa.
La estrategia incluye compras oportunistas de monedas digitales y generación de rendimientos mediante staking, respaldada por una tecnología de inteligencia synthetic para inteligencia de mercado recientemente adquirida. Simultáneamente, Silo Pharma continúa con su enfoque biofarmacéutico, con su medicamento para el TEPT SPC-15 próximo a la presentación de la solicitud IND ante la FDA.
Silo Pharma (나스닥: SILO)가 비트코인, 이더리움, 솔라나에 중점을 둔 암호화폐 자산 관리 분야로 전략적 확장을 발표했습니다. 회사는 이 이니셔티브를 이끌기 위해 암호화폐 인프라 전문가 코윈 유(Corwin Yu)를 새로운 암호화 자문위원회의 첫 멤버로 임명했습니다.
이 전략에는 기회주의적 디지털 화폐 매입과 스테이킹을 통한 수익 창출이 포함되며, 새로 도입한 AI 기반 시장 정보 기술의 지원을 받습니다. 동시에 Silo Pharma는 생명공학 분야에 집중하며, 외상 후 스트레스 장애(PTSD) 치료제 SPC-15의 FDA IND 신청 제출이 임박했습니다.
Silo Pharma (Nasdaq : SILO) a annoncé une enlargement stratégique dans la gestion de trésorerie en cryptomonnaies, en se concentrant sur Bitcoin, Ethereum et Solana. La société a nommé l’skilled en infrastructure crypto Corwin Yu comme premier membre de son nouveau Crypto Advisory Board pour piloter cette initiative.
La stratégie comprend des achats opportunistes de devises numériques et la génération de rendement by way of le staking, soutenue par une nouvelle technologie d’intelligence artificielle pour l’analyse de marché. Parallèlement, Silo Pharma poursuit son orientation biopharmaceutique, avec son médicament contre le PTSD SPC-15 qui approche la soumission de la demande IND à la FDA.
Silo Pharma (Nasdaq: SILO) hat eine strategische Erweiterung im Bereich der Kryptowährungs-Treasury-Verwaltung angekündigt, mit Fokus auf Bitcoin, Ethereum und Solana. Das Unternehmen hat den Krypto-Infrastruktur-Experten Corwin Yu als erstes Mitglied seines neuen Crypto Advisory Boards berufen, um diese Initiative zu leiten.
Die Strategie umfasst opportunistische Käufe digitaler Währungen und Ertragsgenerierung durch Staking, unterstützt durch neu erworbene KI-gestützte Marktanalyse-Technologie. Gleichzeitig bleibt Silo Pharma seinem biopharmazeutischen Fokus treu, wobei das PTSD-Medikament SPC-15 kurz vor der Einreichung des FDA IND-Antrags steht.
Optimistic
- Diversification into cryptocurrency treasury administration with give attention to main digital property
- Appointment of skilled crypto infrastructure skilled Corwin Yu to steer technique
- Acquisition of AI-powered market intelligence know-how for knowledgeable decision-making
- Progress with PTSD drug SPC-15 nearing FDA IND utility stage
Adverse
- Potential volatility and dangers related to cryptocurrency investments
- Dependency on market situations and obtainable capital for technique implementation
- Pending FDA approval for IND utility creates regulatory uncertainty
Concentrating on Multi-Chain Digital Asset Development and Decentralized Finance (DeFi) Integration
SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO), at this time introduced the launch of a cryptocurrency treasury technique which is anticipated to give attention to main digital property, together with Bitcoin, Ethereum, and Solana. The Firm intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield whereas additionally specializing in capital preservation and token appreciation. Expanded implementation of this technique is anticipated to be based mostly on obtainable capital and market situations. Silo has appointed digital asset tech pioneer, Corwin Yu, as the primary member of its newly fashioned Crypto Advisory Board to steer this new technique. To additional this initiative, Silo has lately acquired market intelligence know-how powered by synthetic intelligence, equipping the group with real-time insights to doubtlessly drive smarter, quicker decision-making.
“With the latest rise of profitable cryptocurrency treasury allocations, and rising capital inflows to digital property, we consider there is a chance to doubtlessly create and unlock long-term worth for Silo’s stockholders, beginning now,” stated Silo CEO Eric Weisblum. “We consider that we’re lucky to nominate Corwin Yu as our lead strategic advisor and head of a newly fashioned three-member advisory board overseeing our crypto treasury technique, with 2 different members to be appointed sooner or later.”
Corwin Yu is a senior know-how and buying and selling govt with over 20 years of expertise constructing and managing mission-critical programs for institutional finance. Mr. Yu presently serves as International Head of Digital Property at fintech firm TSImagine, and beforehand he was the founding Chief Know-how Officer of MARKTS, one of many first institutional crypto buying and selling platforms. Along with these management roles, his prior expertise spanned PIMCO, Credit score Suisse, hedge funds and digital asset corporations. As a confirmed chief in cryptocurrency buying and selling infrastructure, fund administration, and regulatory compliance, Mr. Yu has an intensive background in deploying scalable cloud-native platforms and overseeing cross-asset buying and selling methods. His monitor file consists of founding and scaling digital asset buying and selling platforms, managing world engineering and DevOps groups, and delivering safe and compliant crypto custody and treasury options.
“Alongside our launching of a digital asset treasury technique, we stay deeply dedicated to our core biopharmaceutical enterprise centered on modern therapeutics for underserved situations,” Mr. Weisblum continued. “Our lead asset, PTSD drug SPC-15, is finishing last research earlier than submitting an FDA investigational new drug (IND) utility, and if such IND is accepted we might look to begin a first-in-human Section 1 medical trial.”
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury firm. Its therapeutic focus is on addressing underserved situations, together with stress-induced psychiatric issues, continual ache, and central nervous system (CNS) ailments. The Firm’s portfolio consists of modern packages corresponding to SPC-15 for PTSD, SP-26 for fibromyalgia and continual ache, and preclinical property concentrating on Alzheimer’s illness and a number of sclerosis. Silo’s analysis is carried out in collaboration with main universities and laboratories.
Ahead-Trying Statements
This information launch incorporates “forward-looking statements” throughout the which means of the “secure harbor” provisions of the Personal Securities Litigation Reform Act of 1995. These statements are recognized utilizing phrases “might”, “consider”, “anticipate”, “intend”, “estimate”, “count on”, “could”, “proceed”, “predict”, “potential”, and related expressions which are meant to determine forward-looking statements. Such statements contain recognized and unknown dangers, uncertainties, and different elements that might trigger the precise outcomes of Silo Pharma, Inc. (“Silo” or “the Firm”) to vary materially from the outcomes expressed or implied by such statements, together with modifications to anticipated sources of revenues, future financial and aggressive situations, difficulties in growing the Firm’s know-how platforms, retaining and increasing the Firm’s buyer base, fluctuations in shopper spending on the Firm’s merchandise and different elements. Accordingly, though the Firm believes that the expectations mirrored in such forward-looking statements are affordable, there might be no assurance that such expectations will show to be appropriate. The Firm disclaims any obligations to publicly replace or launch any revisions to the forward-looking data contained on this press launch, whether or not on account of new data, future occasions, or in any other case, after the date of this press launch or to mirror the prevalence of unanticipated occasions besides as required by legislation.
Contact
800-705-0120
investors@silopharma.com
FAQ
What’s Silo Pharma’s (SILO) new cryptocurrency treasury technique?
Silo Pharma plans to make opportunistic purchases of Bitcoin, Ethereum, and Solana, using staking for yield era whereas specializing in capital preservation and token appreciation.
Who’s Corwin Yu and what’s his position at Silo Pharma?
Corwin Yu is a senior know-how and buying and selling govt appointed as the primary member of Silo’s new Crypto Advisory Board. He presently serves as International Head of Digital Property at TSImagine and has over 20 years of institutional finance expertise.
How will Silo Pharma’s crypto technique have an effect on its pharmaceutical enterprise?
The corporate states it stays deeply dedicated to its core biopharmaceutical enterprise, with the crypto technique operating parallel to its pharmaceutical growth, together with the development of PTSD drug SPC-15.
What’s the standing of Silo Pharma’s PTSD drug SPC-15?
SPC-15 is finishing last research earlier than submitting an FDA investigational new drug (IND) utility, with plans to start Section 1 medical trials if accepted.
What know-how will Silo Pharma use for its crypto treasury administration?
The corporate has acquired AI-powered market intelligence know-how to offer real-time insights for decision-making in its cryptocurrency treasury administration.
